PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FDA withdraws one of BMS chemo drug indications

The U.S. FDA announced it withdrew the new drug application approval for Celgene’s — a Bristol-Myers Squibb Company — cancer drug. Teva Pharmaceuticals’ version is in the same boat.

While the formal decision was just recently announced, the companies had requested that the administration withdraw approval for one indication last year.

The saga actually started back in August of 2020, when Celgene submitted clinical trial results indicating the study failed to meet its primary endpoint of progression-free survival. The trial, Ro-CHOP,  compared the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL). On May 14, 2021, Celgene informed FDA that after careful consideration, it had decided to voluntarily withdraw the PTCL indication from Istodax (romidepsin) for injection.

The FDA approved an additional indication for Celgene’s NDA for Istodax specifically for the treatment of PTCL back in June 2011. The accelerated approval for PTCL included the required postmarketing clinical trial.

The drug is a histone deacetylase inhibitor antineoplastic agent used as a chemotherapy regimen for T-cell lymphoma affecting the skin. Specifically, the drug was given to patients who had been already treated for their cancer with other therapies. Istodax worked by inhibiting histone deacetylases, which act as on and off switches for genes. Its effects helped regulate cell growth and death, the biological processes responsible for tumor formation and spread.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026